S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00

Icosavax Stock Forecast, Price & News

+0.54 (+2.05 %)
(As of 10/27/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
105,093 shs
Average Volume
197,437 shs
Market Capitalization
$1.06 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ICVX News and Ratings via Email

Sign-up to receive the latest news and ratings for Icosavax and its competitors with MarketBeat's FREE daily newsletter.

Icosavax logo

About Icosavax

Icosavax Inc. is a biopharmaceutical company which focuses on life-threatening respiratory diseases. The company's virus-like particle platform technology involved in developing vaccines against infectious diseases. Icosavax Inc. is based in SEATTLE.


Icosavax (NASDAQ:ICVX) Shares Gap Down to $25.50
October 25, 2021 |  americanbankingnews.com
Icosavax (NASDAQ:ICVX) Stock Price Down 9.4%
October 22, 2021 |  americanbankingnews.com
Icosavax (NASDAQ:ICVX) Shares Gap Up to $26.73
October 21, 2021 |  americanbankingnews.com
Icosavax (NASDAQ:ICVX) Shares Up 11.2%
October 20, 2021 |  americanbankingnews.com
Icosavax Inc (NASDAQ:ICVX) Sees Large Increase in Short Interest
October 15, 2021 |  americanbankingnews.com
Icosavax (NASDAQ:ICVX) Shares Gap Up to $25.59
October 14, 2021 |  americanbankingnews.com
Icosavax (NASDAQ:ICVX) Shares Gap Down to $30.39
October 11, 2021 |  americanbankingnews.com
Icosavax (NASDAQ:ICVX) Stock Price Down 8.6%
October 8, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales


Pretax Margin




Free Float
Market Cap
$1.06 billion
Next Earnings Date
12/13/2021 (Estimated)
Fiscal Year End
December 31
Not Optionable


Overall MarketRank

1.83 out of 5 stars

Medical Sector

767th out of 1,372 stocks

Biological Products, Except Diagnostic Industry

115th out of 197 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Icosavax (NASDAQ:ICVX) Frequently Asked Questions

Is Icosavax a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Icosavax in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Icosavax stock.
View analyst ratings for Icosavax
or view top-rated stocks.

What stocks does MarketBeat like better than Icosavax?

Wall Street analysts have given Icosavax a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Icosavax wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Icosavax?

Icosavax saw a increase in short interest in September. As of September 30th, there was short interest totaling 736,300 shares, an increase of 107.4% from the September 15th total of 355,000 shares. Based on an average daily trading volume, of 280,600 shares, the short-interest ratio is currently 2.6 days. Approximately 3.1% of the shares of the company are short sold.
View Icosavax's Short Interest

When is Icosavax's next earnings date?

Icosavax is scheduled to release its next quarterly earnings announcement on Monday, December 13th 2021.
View our earnings forecast for Icosavax

How were Icosavax's earnings last quarter?

Icosavax Inc (NASDAQ:ICVX) posted its quarterly earnings data on Monday, September, 13th. The company reported ($2.86) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.90) by $1.96. The business had revenue of $1.90 million for the quarter, compared to the consensus estimate of $3.10 million.
View Icosavax's earnings history

What price target have analysts set for ICVX?

4 brokers have issued 12-month target prices for Icosavax's stock. Their forecasts range from $45.70 to $50.00. On average, they anticipate Icosavax's stock price to reach $48.57 in the next twelve months. This suggests a possible upside of 81.0% from the stock's current price.
View analysts' price targets for Icosavax
or view top-rated stocks among Wall Street analysts.

When did Icosavax IPO?

(ICVX) raised $150 million in an IPO on Thursday, July 29th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share.

What is Icosavax's stock symbol?

Icosavax trades on the NASDAQ under the ticker symbol "ICVX."

When did the company's quiet period expire?

Icosavax's quiet period expired on Tuesday, September 7th. Icosavax had issued 12,133,333 shares in its initial public offering on July 29th. The total size of the offering was $181,999,995 based on an initial share price of $15.00. During the company's quiet period, insiders and any underwriters that worked on the IPO were restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Icosavax?

Shares of ICVX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Icosavax's stock price today?

One share of ICVX stock can currently be purchased for approximately $26.83.

How much money does Icosavax make?

Icosavax has a market capitalization of $1.06 billion.

How many employees does Icosavax have?

Icosavax employs 2,021 workers across the globe.

What is Icosavax's official website?

The official website for Icosavax is icosavax.com.

How can I contact Icosavax?

The company can be reached via email at [email protected].

This page was last updated on 10/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.